Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of QGC001 after hospitalization for worsening chronic heart failure
2015-005607-92Phase 2Terminated
- Sponsor
- Quantum Genomics
- Start
- Mar 2016
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic heart failure (CHF) and left ventricular systolic dysfunction (LVSD) comparing QGC001 up-titration with Placebo (2 arms). Primary endpoints: NT-proBNP responder rate at Day 28 and Blood pressure changes through Day 28. Started Mar 2016; status: terminated.
02
Drugs
firibastat
03
Conditions
chronic heart failure (CHF)left ventricular systolic dysfunction (LVSD)
Beyond the preview
Go deeper on 2015-005607-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005607-92.